COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00703339
Recruitment Status : Terminated (Lack of enrollment to the trial. Very difficult population to recruit.)
First Posted : June 23, 2008
Results First Posted : May 10, 2012
Last Update Posted : May 11, 2018
Information provided by (Responsible Party):
Lung Biotechnology PBC

Brief Summary:
The purpose of this study is to establish single-dose tolerability of inhaled treprostinil sodium in idiopathic pulmonary fibrosis (IPF) patients with pulmonary hypertension, and to explore the acute hemodynamic effects over a range of tolerable doses. The safety and pharmacodynamic information obtained from this study will inform the design and conduct of future studies in inhaled treprostinil sodium in this population.

Condition or disease Intervention/treatment Phase
Idiopathic Pulmonary Fibrosis Pulmonary Hypertension Drug: Treprostinil sodium for inhalation Phase 2

Detailed Description:
This is Phase 2, multi-center, open-label, four-cohort study in subjects with pulmonary hypertension (PH) associated with idiopathic pulmonary fibrosis (IPF). Each cohort of four subjects will receive a single dose of inhaled treprostinil sodium. Cohorts will be enrolled sequentially, starting with the lowest dose of 18 mcg. Each cohort escalate by 18 mcg increments, resulting in four cohorts of 18, 36, 54, and 72 mcg doses. Decisions to escalate to the next dose cohort will be based upon the data from the previous completed lower dose cohort of four subjects. Approximately 16 subjects are expected to receive study drug,and approximately four center in the United States with expertise in IPF will participate in this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-Dose, Dose-Escalating Study Exploring the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Inhaled Treprostinil Sodium Using the Nebu-Tec OPTINEB Inhalation Device in Patients With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
Study Start Date : June 2008
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Intervention Details:
  • Drug: Treprostinil sodium for inhalation

    Administration of inhaled treprostinil sodium 0.6 mg/ml in 3mL ampoules Duration of Treatment: single dose


    • Cohort 1: dosed at 3 breaths (18 mcg)
    • Cohort 2: dosed at 6 breaths (36 mcg)
    • Cohort 3: dosed at 9 breaths (54 mcg)
    • Cohort 4: dosed at 12 breaths (72 mcg)

    The decision to advance to the next cohort will be made after review of all safety information including vital signs, physical examination, clinical laboratory tests, ECGs, and adverse events.

Primary Outcome Measures :
  1. Safety and Tolerability of Inhaled Treprostinil Sodium in Patients With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis,Reported as Number of Participants With Adverse Events [ Time Frame: 3-5 days ]
    Safety and Tolerability evaluation include any observed or reported changes in vital signs, ECGs, clinical chemistry ,hematological or urinalysis, and any reported symptoms following a single dose administration on the day of dosing and up to the final visit 3-5 days later. Adverse events will be tabulated by total incidence and by individual patient, and the severity, causality and outcomes will also be documented. Each cohort of 4 patients will be fully evaluated as described before proceeding to the escalation to the next dose.

Secondary Outcome Measures :
  1. Pharmacokinetic (PK) Parameters After a Single Dose of Inhaled Treprostinil and Acute Hemodynamic Effects. [ Time Frame: acute ]
    PK samples will be collected at frequent intervals up to 4 hours following single dosing . Hemodynamic parameters at 4 hours post dosing include heart rate, pulmonary arterial pressure, systemic arterial pressure, right atrial pressure, pulmonary capillary wedge pressure, mixed venous oxygen saturation and cardiac output.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 35 to 80 years of age
  • Male or female
  • Diagnosis of IPF

    1. Investigator diagnosis based on history, physical examination, HRCT,and pulmonary function testing
    2. Clinical symptoms of IPF for at least three months prior to Visit 1
    3. High Resolution CT scan showing definite or probable IPF (any time in the past). Bibasilar reticular abnormalities with minimal ground glass opacities on HRCT scan must also be present (at any time in the past)
    4. Surgical lung biopsy showing usual interstitial pneumonia, or transbronchial lung biopsy that was not diagnostic of an alternative condition. For patients younger than 50 years, a surgical lung biopsy is required (at any time in the past)
    5. FVC ≥ 30 % and < 70% of predicted value within three months prior to Visit 1
    6. DLCO ≥ 15% and <70% of predicted value within three months prior to Visit 1.
  • Diagnosis of PH

    1. Previously documented radiographic or echocardiographic findings suggestive of pulmonary hypertension
    2. Prior right heart catheterization diagnostic of pre-capillary pulmonary hypertension. [The presence of pre-capillary pulmonary hypertension will be verified by right heart catheterization during Study Visit 3, before enrollment and administration of study drug].
  • No changes in concomitant medications prescribed to treat PAH or IPF for 30 days to Visit 1
  • Females of childbearing potential may participate only if they are not currently pregnant or lactating and are either one of the following:

    1. Surgically sterile
    2. At least 1 year post-menopausal
    3. Practicing an acceptable method of birth control for at least 30 prior to the Visit 1 with plans to continue this method for the duration of their participation in the study.
  • An echocardiogram will be performed at Visit 2. Only those subjects with Visit 2 echocardiographic findings that strongly suggest the presence of pulmonary hypertension, will proceed to Visit 3. Acceptable findings include any of the following:

    1. TR velocity greater than 3.5 m/sec
    2. TR velocity greater than 3.0 m/sec with right ventricular enlargement or dysfunction
  • A right heart catheterization will be performed at Visit 3. Only those subjects with Visit 3 right heart catheterization findings that establish the presence of pulmonary hypertension will proceed to enrollment and study drug administration. Acceptable findings must include all of the followings:

    1. mean PA pressure equal or greater than 25 mm HG
    2. pulmonary capillary wedge pressure equal or less than 15 mm Hg
    3. pulmonary vascular resistance greater than 3 mmHg/min

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if ANY of the following criteria apply:

  • History of known or suspected pulmonary embolism or deep venous thrombosis
  • Clinical evidence of left-sided heart disease
  • Presence of atrial fibrillation (determined from 12 lead ECG at Visit 1 or 2)
  • Other medical condition or drug exposure known to be associated with pulmonary fibrosis (e.g., rheumatoid arthritis, lupus, scleroderma, etc.) or pulmonary arterial hypertension (e.g., connective tissue disease, congenital heart disease, portal hypertension, HIV infection, drug and toxins, etc.)
  • Upper or lower respiratory infection within 30 days prior to Visit 1
  • Hospitalization for respiratory illness within 30 days prior to Visit 1
  • Diagnosis of any other clinically significant illness that, in the opinion of the investigator, might put the subject at risk of harm from participation in the study or might adversely effect the interpretation of the study data. (e.g., significant liver or kidney disease, etc.)
  • History of recurrent symptoms that might, in the opinion of the investigator, adversely effect the interpretation of the study data (e.g., severe headaches, diarrhea, jaw pain, syncope, nausea,vomiting, etc.)
  • Current treatment with any medication that is approved by the US FDA to treat pulmonary hypertension (e.g., epoprostenol(Flolan), treprostinil (Remodulin), iloprost (Ventavis), bosentan(Tracleer), ambrisentan (Letairis), sildenafil (Revatio), etc.,), or tadalafil (Cialis)
  • Current treatment with an anticoagulant
  • A reactive screen for hepatitis B surface antigen, or the hepatitis C antibody, or HIV antibody as tested at Visit 1.
  • Use of any inhaled tobacco products or significant history of drug abuse within 90 days prior to Visit 1
  • The subject has an echocardiogram performed at Visit 2 that demonstrate findings that are indicative of left ventricular or valvular disease. Findings that will be considered evidence of left ventricular or valvular disease, and therefore exclude the subject from proceeding to Visit 3 are any of the following:

    1. LVEF < 55%
    2. Moderate to Severe mitral regurgitation or aortic regurgitation
    3. Any mitral stenosis or aortic stenosis
    4. Grade 2 or 3 diastolic dysfunction by Doppler
  • Use of any investigational drug, or participation in any investigational study within the 30 days prior to Visit 1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00703339

Layout table for location information
United States, California
UCSD Medical Center m/c7381
La Jolla, California, United States, 92037
UC Davis Medical Center/Advanced Lung Disease and LungTransplant Program
Sacramento, California, United States, 95817
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109-5853
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232-5735
United States, Texas
UTWS Medical Center Dallas/St. Paul Univ. Hospital
Dallas, Texas, United States, 75390-8550
United States, Virginia
Inova Heart and Vascular Institute
Falls Church, Virginia, United States, 22042
Sponsors and Collaborators
Lung Biotechnology PBC
Layout table for additonal information
Responsible Party: Lung Biotechnology PBC Identifier: NCT00703339    
Other Study ID Numbers: TREINH-IPF-201
First Posted: June 23, 2008    Key Record Dates
Results First Posted: May 10, 2012
Last Update Posted: May 11, 2018
Last Verified: May 2012
Keywords provided by Lung Biotechnology PBC:
fibrosis, pulmonary
hypertension, pulmonary
exercise, aerobic
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Pulmonary
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Idiopathic Interstitial Pneumonias
Lung Diseases, Interstitial
Antihypertensive Agents